Cargando…
Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report
BACKGROUND: Targeted therapy with tyrosine kinase inhibitors has been shown to reduce tumor volumes and prolong the survival of patients with metastatic renal cell carcinoma. Tyrosine kinase inhibitors, particularly sunitinib, have recently been used in neoadjuvant and presurgical settings. Axitinib...
Autores principales: | Koie, Takuya, Ohyama, Chikara, Okamoto, Akiko, Yamamoto, Hayato, Imai, Atsushi, Hatakeyama, Shingo, Yoneyama, Takahiro, Hashimoto, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222084/ https://www.ncbi.nlm.nih.gov/pubmed/24267160 http://dx.doi.org/10.1186/1756-0500-6-484 |
Ejemplares similares
-
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
por: Koie, Takuya, et al.
Publicado: (2015) -
A Case of Primary Renal Carcinoid Tumor
por: Tanaka, Toshikazu, et al.
Publicado: (2015) -
Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma
por: Hosogoe, Shogo, et al.
Publicado: (2017) -
Robotic cross‐folded U‐configuration intracorporeal ileal neobladder for muscle‐invasive bladder cancer: Initial experience and functional outcomes
por: Koie, Takuya, et al.
Publicado: (2018) -
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer
por: Koie, Takuya, et al.
Publicado: (2014)